Source: Iceni Gold
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Iceni Gold (ICL) confirms the high-grade gold vein discovery made at its Everleigh Well target area in Western Australia
  • Preliminary assays returned a peak value of 18,207g/t gold at the Christmas Gift anomaly, with the average of the duplicate assays being 16,900g/t gold
  • The multi-element assays also measured 2500g/t silver, 426g/t copper, 5.8g/t mercury, 20g/t tungsten, 5ppb platinum and 114ppb palladium
  • The company now turns its focus to designing a drill campaign for the targets at Everleigh Well
  • Shares are up 11 per cent to 11 cents at 2:36 pm AEST

Iceni Gold (ICL) has confirmed a high-grade gold vein discovery made at its Everleigh Well target area in Western Australia.

Preliminary assay results returned a peak value of 18,207 grams per tonne (g/t) gold at the Christmas Gift anomaly, with the average of the duplicate assays being 16,900g/t gold.

The multi-element assays also measured 2500g/t silver, 426g/t copper, 5. g/t mercury, 20g/t tungsten, 5 parts per billion (ppb) platinum and 114ppb palladium.

“Ongoing fieldwork and sampling confirms the presence of mineralisation within the Christmas Gift soil anomaly,” Iceni Technical Director David Nixon said.

“Multi-element assays from the high-grade outcropping quartz vein with visible gold in the Everleigh target area show a clear geochemical signature for this mineralisation.”

The company is now turning its efforts to designing an exploration drill campaign for the targets at Everleigh Well.

Iceni was up 11.1 per cent to 11 cents at 2:36 pm AEST.

ICL by the numbers
More From The Market Online
The Market Online Video

Market Close: Consumer stocks drag market lower; Alara starts copper production in Oman

The ASX200 has closed the day down 0.15 per cent at 7724 points.
The Market Online Video

Orcoda welcomes Maree Adshead as Non-Executive Director

Orcoda (ASX:ODA) has welcomed Maree Adshead as an independent Non-Executive Director.

Cynata Therapeutics advances Phase 2 trial for high-risk aGvHD treatment

The market has responded favourably to Cynata Therapeutics' announcement regarding its Phase 2 clinical trial on…
The Market Online Video

Market Update: ASX trades flat as materials leads the market

The ASX200 is trading flat this afternoon, up just .10 of a per cent in line…